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Introduction
Diabetic patients have a high risk of hyperglycaemia, a 
condition that is considered to be a major cause of cardio-
vascular disease (CVD).1 Diabetes is characterised by the 
development of specific micro- and macrovascular compli-
cations and by high incidence of accelerated atherosclero-
sis.2 Hyperglycaemia-caused endothelial dysfunction plays 
a key role in the pathogenesis of diabetes complications 
and numerous studies have linked the activation of protein 
kinase C (PKC) to the diabetic state.3 PKC activation regu-
lates vascular permeability and is involved in endothelial 
cell activation, abnormal angiogenesis, synthesis of the 
extracellular matrix, excessive apoptosis, leukocyte adhe-
sion and cytokine production.4
In addition to glucose itself, increased vascular 
atherosclerosis is further caused by the degradation prod-
ucts (GDPs) of glucose.5 Reactive GDPs, such as 
3,4-  dideoxyglucosone-3-ene (3,4-DGE), react with pro-
teins to form advanced glycation end products (AGEs) in 
the circulation.6–8
Severely hyperglycaemic patients typically suffer 
from complications such as infections and decreased 
wound healing.9 Postoperative hyperglycaemia is also a 
recognised risk factor for postoperative surgical site infec-
tions that leads to increased rehospitalisation, prolonged 
length of hospital stay and increased health-care costs.10 
Highly reactive GDPs, such as 3,4-DGE, react instantly with 
different molecules, while others, such as 3-deoxyglucosone 
(3-DG), remain in the circulation.11 The amount of 3-DG in 
the serum of a healthy human is low, but increases two-fold 
with disease such as diabetes and threefold in uraemia.12 
Furthermore, 3-DG is converted to the more reactive 3,4-
DGE through equilibrium.13 3,4-DGE was recently demon-
strated to decrease neutrophil viability, impair immune 
responses and decrease bacterial killing.8 Hyperglycaemia 
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and GDPs are further known to induce caspase-mediated 
apoptosis and oxidative stress in endothelial cells and neu-
trophils.8,14,15 AGE activation of endothelial cells stimu-
lates a host of proinflammatory events, such as the secretion 
of tumour necrosis factor alpha (TNFα) and interleukin-6 
(IL-6), but also the induction of chemotactic cytokines such 
as interleukin-8 [IL-8; chemokine (C-X-C motif) ligand 
8 (CXCL8)] and chemokine (C-C motif) ligand 2 (CCL2; 
MCP-1), leading to increased endothelial inflammation and 
leukocyte recruitment.16,17 Hyperglycaemia-induced reac-
tive oxygen species (ROS) production leads also to upregu-
lation of the intercellular adhesion molecule-1 (ICAM-1) 
and vascular cellular adhesion molecule-1 (VCAM-1).18 
The sum of these events leads to adhesion and migration of 
leukocytes across endothelial cells, which play an impor-
tant role in the development of atherosclerosis.19
Citrate is an intermediate in the citric acid cycle and is 
widely used in the food and drug industry because of its 
buffer, anticoagulant and antioxidant capacities. As a chela-
tor, citrate is able to bind calcium and metals that catalyse 
the production of ROS. Different chelators have been eval-
uated against the development of diabetic complications in 
numerous in vivo studies, but the results are not uniformly 
positive.20–22 Citrate addition during dialysis was shown to 
improve clinical parameters and to decrease inflamma-
tion,23–25 but there are no studies published on citrate 
treatment during hyperglycaemic conditions. Another anti-
oxidant with chelating properties is gluconate, which was 
recently shown to improve endothelial function.26 Although 
the clinical usage of citrate is gaining popularity, in-depth 
knowledge about its anti-inflammatory mechanisms are 
unknown. The aim of this study was to investigate the anti-
inflammatory capacity of citrate and the combination of 
citrate and gluconate on hyperglycaemia- or 3,4-DGE-
damaged endothelial cells.
Methods
Cell culture
Primary human umbilical vein endothelial cells (HUVECs) 
(Clonetics; Lonza Cologne GmbH, Cologne, Germany) 
were obtained and cultured in endothelial cell growth 
medium (EGM®-2; Clonetics; Lonza Cologne GmbH, 
Cologne, Germany) supplemented with the EGM®-2 
BulletKit® [hydrocortisone, 0.4% human fibroblast growth 
factor-basic (hFGF-b); 0.1% vascular endothelial growth 
factor (VEGF); 0.1% recombinant analogue of insulin-like 
growth factor-1(R3-IGF-1); 0.1% ascorbic acid; 0.1% hepa-
rin; 2% fetal bovine serum (FBS); 0.1% hEGF and 0.1% 
gentamicin sulfate and amphotericin-B (GA-1000); incuba-
tion: 37  °C, 5% CO2] (Clonetics, Lonza Cologne GmbH, 
Cologne, Germany). The cells were used at passages 2–5, 
according to the manufacturer’s instructions.
Dose-response evaluation
Endothelial cells were exposed to different concentrations 
of citrate (0.25, 0.8, 1.0, 1.5, 2.0 and 5.0  mM) and gluco-
nate (0.25, 0.8, 1.0, 1.5, 2.0 and 5.0 mM) for 48 h. The pro-
portions of living cells were evaluated by the neutral red 
(NR) uptake assay.27
Sample preparation
Endothelial cells were cultured in six-well plates (BD 
Biosciences, Stockholm, Sweden) until approximately 
80% confluent. The cells were treated with 30  mM 
D-glucose (Merck KGaA, Darmstadt, Germany) to mimic 
the state of hyperglycaemia or 50 µM 3,4-DGE, which was 
extracted from glucose-containing fluid according to 
Linden et al.,28 alone or with the addition of 0.8 mM citrate 
(trisodium citrate dihydrate; Merck KGaA, Darmstadt, 
Germany) or a combination (henceforth referred to as the 
‘CAG combination’) of 0.8  mM citrate and 1  mM gluco-
nate (sodium gluconate; Jungbunzlauer AG, Basel, 
Switzerland) dissolved in supplemented EGM-2 medium 
followed by incubation (37  °C, 5% CO2) for 48  h. GDP 
concentration was chosen according to previous studies8 
and the concentrations of citrate and the CAG combination 
were selected after dose-response studies (supplementary 
Figure 1). Endothelial cells treated with EGM-2 medium 
were used as a negative control. As an additional control, 
the cells were also treated with 0.8 mM citrate or with the 
CAG combination.
Detection of apoptosis and necrosis
After incubation with different combinations, the cells were 
detached [trypsin-ethylenediamine tetraacetic acid (EDTA) 
for about 5 min at room temperature, followed by the addi-
tion of a trypsin inhibitor], washed in phosphate-buffered 
saline (PBS; twice, 5  min, 1000  rpm) and stained with 
annexin V-Alexa Fluor®488 (Life Technologies Europe BV, 
Stockholm, Sweden) (1:100, 15 min in the dark on ice) to 
detect apoptosis and 7-aminoactinomycin D (7-AAD; BD 
Via-Probe, BD Pharmingen Biosciences, San Diego, 
California, USA) (1:100, 15 min in the dark on ice) to test 
for late apoptosis and necrosis. The fluorescence was eval-
uated using a EPICS® XL-MCL™ flow cytometer (Beckman 
Coulter Inc., Brea, California, USA), and fluorescence 
intensity was standardised using Flow-Set fluorospheres 
(Beckman Coulter Inc., Brea, California, USA).
Apoptosis was further visualised by confocal micros-
copy. After incubation with different combinations, the cells 
were harvested on glass slides in a cytospin2 centrifuge (RP 
centrifuge; Hettich Rotanta, Malmö, Sweden) at 600 rpm for 
5 min and fixed in 100% methanol. Before staining, the cells 
were permeabilised with 0.25% Triton-X 100 (VWR 
International, Göteborg, Sweden) in PBS with 5% FBS for 44  Diabetes & Vascular Disease Research 9(1)
10 min. Slides were incubated with anti-chemokine (C-X-C 
motif) receptor 2 [CXCR2; interleukin-8 receptor, beta 
(IL8RB) antibody or control immunoglobulin G (IgG) anti-
body (10 µg/ml; mouse IgG isotype control; R&D Systems, 
Copenhagen, Denmark)] for 40  min at room temperature. 
The slides were washed in PBS and incubated with second-
ary goat anti-mouse IgG antibodies (Alexa Fluor® 488, 
Invitrogen Corporation, Carlsbad, California, USA) in a 
dilution of 1:200 for 40 min in the dark at room temperature. 
Staining of DNA was performed by incubating the cells with 
propidium iodide (1  mg/ml) for 15  min in the dark at room 
temperature. After washing in PBS, the slides were exam-
ined with the LSM 510 confocal laser scanning microscope 
(Carl Zeiss MicroImaging GmbH, Göttingen, Germany).
PKC activation
Cells were treated with glucose/3,4-DGE and citrate/CAG as 
previously described and washed with PBS containing 
0.2  mM phenylmethylsulfonyl fluoride (PMSF), 1  µg/ml 
pepstatin A, 5 µg/ml leupeptin (Sigma-Aldrich Sweden AB, 
Stockholm, Sweden) and a complete protease inhibitor cock-
tail (Roche Diagnostics GmbH, Mannheim, Germany) and 
lysed in modified radio immunoprecipitation assay (RIPA) 
[50 mM  2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic 
acid (HEPES), 150  mM NaCl, 2  mM EDTA, 50  mM ZnCl2, 
1% nonyl phenoxylpolyethoxylethanol (NP-40), 0.1% 
sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS) 
containing the same protease inhibitors]. Protein concentra-
tions were measured with the detergent compatible (DC™) 
protein assay (Bio-Rad Laboratories, Hercules, California, 
USA). Equal amounts of protein were separated by SDS-
polyacrylamide gel electrophoresis (PAGE) and blotted onto 
polyvinylidene fluoride (PVDF) membranes. Membranes 
were saturated with non-fat dry milk or bovine serum albu-
min (BSA) and incubated with mouse monoclonal antibodies 
against PKC-βII (Millipore AB, Solna, Sweden) (all 1:500–
1000) or mouse anti-glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) antibody as loading control (1:3000–5000; 
Novus Europe, Cambridge, UK). Bound antibodies were 
detected with rabbit anti-mouse horseradish peroxidase 
(HRP)-conjugated antibody (1:50,000–200,000; Novus 
Europe, Cambridge, UK) using the ECL Plus Western blot-
ting reagent (GE Healthcare UK Ltd, Little Chalfont, UK) 
and the GelDoc equipment (Bio-Rad Laboratories AB, 
Sundbyberg, Sweden). To quantify protein levels, band inten-
sity was measured with the ImageJ software version 1.24 
(National Institutes of Health, Bethesda, Maryland, USA) 
and normalised against GAPDH. If required, membranes 
were stripped with Restore Western Blot Stripping Buffer 
(Thermo Fisher Scientific Inc., Rockford, Illinois, USA), 
blocked and reprobed with new antibodies.
ICAM-1 expression
After exposure to different combinations, the endothelial 
cells were enzymatically detached according to the manu-
facturer’s instructions and washed in PBS (twice, 5  min, 
1000 rpm) followed by the addition of antibodies for expres-
sion of the VCAM-1 (10 µg/ml) or ICAM-1 (10 µg/ml) adhe-
sion molecules (R&D Systems, Copenhagen, Denmark). 
Cells were incubated in the dark on ice for 30  min, then 
washed in PBS (twice, 5 min, 1000 rpm), and stained with 
secondary rabbit anti-mouse IgG-fluorescein isothiocy-
anate (FITC) rabbit f(ab′)2 antibody (10  µg/ml) (Dako 
Sweden AB, Stockholm, Sweden) and incubated for 15 min 
in the dark on ice. After an additional washing step (PBS, 
twice, 5  min, 1000  rpm) the expression of ICAM-1 and 
VCAM-1 was analysed using the EPICS® XL-MCL™ flow 
cytometer (Beckman Coulter Inc., Brea, California, USA), 
and fluorescence intensity was standardised using Flow-Set 
fluorospheres (Beckman Coulter Inc., Brea, California, 
USA). An IgG negative control (Life Technologies Europe 
BV, Stockholm, Sweden) was used as a negative control.
Neutrophil migration
HUVECs were grown on Transwell® inserts (12-well, 
3  µM pore size; Sigma-Aldrich Chemie GmbH, Munich, 
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Figure 1.  Citrate and citrate/gluconate decrease cell death. 
Glucose (a) and 3,4-dideoxyglucosone-3-ene (3,4-DGE) 
(b) treatment of endothelial cells increased total cell death. The 
figure shows the percentage of total cell death as well as the 
parts that are apoptotic (light grey) and necrotic (dark grey). 
Citrate and the 0.8 mM citrate and 1 mM gluconate (CAG) 
combination reduced apoptosis and necrosis after 48 h of 
incubation together with glucose (a) or 3,4-DGE (b). Glucose 
or 3,4-DGE treatment was compared to medium control, 
and citrate and CAG combination treatment of glucose and 
3,4-DGE-damaged cells was compared to the respective additive. 
The results are the mean (± SEM) of four different experiments 
(a and b) (***p < 0.001, **p < 0.01).Bryland et al.  45
Germany) in EGM-2 medium, as previously described.29 As 
a control, cell viability was analysed by trypan blue exclu-
sion assay according to the manufacturer’s instructions 
(Sigma-Aldrich Chemie GmbH, Munich, Germany). The 
cell growth medium was replaced with medium containing 
glucose, 3,4-DGE or combinations of glucose/3,4-DGE and 
citrate/CAG as in the experiments above, and the cells were 
incubated for 48  h. Cells treated with medium and cells 
treated with 0.8  mM citrate or the CAG combination were 
used as negative controls. Human neutrophil isolation and 
transmigration assays were performed as previously 
described.29 Briefly, 0.5 ml fresh culture medium was added 
to the top well, and fresh medium or medium containing the 
different combinations and Escherichia coli (108 bacteria/
cell, 1.5  ml) was added to the bottom well.8,29 The cluster 
plates were then incubated at 37 °C and at 5% CO2 atmos-
phere for 24  h, a time that induced maximal neutrophil 
migration across the endothelial monolayer. Neutrophils 
(1.5 × 106, 0.5 ml) were added to the top well. After 3 h, sam-
ples were taken from the bottom well for neutrophil count-
ing by Cell Counter (Sysmex UK Ltd, Milton Keynes, UK) 
and analysed for cytokines.
Cytokine secretion
Secretion of IL-6 and CXCL8 by the infected endothelial 
cells was quantified in supernatants by enzyme-linked 
immunosorbent assay (ELISA; R&D Systems, Sweden) 
according to the manufacturer’s instructions.
Statistical analysis
All data are shown as mean ± SEM. Each experiment was 
repeated 3–4 times. The statistical difference was investigated 
using the Mann–Whitney U test (***p ≤ 0.001, **p < 0.01, 
*p < 0.05, ns = not significant).
Results
Evaluation of optimal concentrations
To determine optimal antioxidant concentrations, we 
analysed the effect of the antioxidants on cell survival by 
dose-response curve studies (supplementary Figure 1). 
Endothelial cell viability was not affected by citrate or glu-
conate concentrations up to 5 mM as determined by the NR 
uptake assay.
Citrate treatment decreases cell mortality
To investigate whether citrate or the combination of citrate 
and gluconate influence the cause of cell death, endothelial 
cells were exposed to glucose and 3,4-DGE in the presence 
or absence of citrate or CAG combination (Figure 1). 
Natural cell death (medium control) was 22%, of which 5% 
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Figure 2.  Citrate and citrate/gluconate decrease apoptosis 
and PKC-βII expression. (a) Confocal microscopy revealed 
a significant increase of nuclear fragmentation in glucose- 
or 3,4-DGE-treated epithelial cells compared to control 
(indicated by the arrows). The cellular membrane was stained 
green for chemokine (C-X-C motif) receptor 2 (CXCR2) 
with primary mouse antibodies followed by labelling 
with secondary antibodies conjugated with fluorescein 
isothiocyanate (FITC) (R&D Systems, Copenhagen, Denmark). 
Cell nuclei were stained with propidium iodide (red). Original 
magnification × 300. (b and c) Western blot analysis revealed 
a continuous basal PKC-βII expression in endothelial cells. 
Treatment with glucose or 3,4-DGE increased the amount 
of PKC-βII proteins. Citrate or 0.8 mM citrate and 1 mM 
gluconate (CAG) treatment of hyperglycaemia-damaged cells 
decreased PKC-βII expression down to background level. 
Quantification of band intensity was performed using the 
ImageJ version 1.24 software (National Institutes of Health, 
Bethesda, Maryland, USA) and normalised to glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) protein level. The 
results are the mean of three different experiments 
(± SEM) (**p < 0.01).46  Diabetes & Vascular Disease Research 9(1)
was caused by apoptosis and 17% was caused by necrosis. 
Incubation of the endothelial cells with glucose or 3,4-DGE 
significantly increased the total number of dead cells to 
46% and to 63% respectively compared to control (Figure 
1a and 1b).
Glucose treatment of HUVECs increased the fraction of 
both apoptotic and necrotic cells (up to 11% and to 34%), 
while 3,4-DGE-treated HUVECs increased higher frac-
tions of both apoptotic and necrotic cells (up to 14% and to 
49%) compared to the control (Figure 1a and Figure 2a). 
The presence of citrate or CAG combination decreased the 
glucose-induced cell death drastically. Citrate treatment 
decreased the apoptotic fraction down to the level of the 
control (6%), as did the CAG combination which decreased 
glucose-induced cell death to 5%. Glucose-induced necro-
sis was decreased to 26% and 27% with citrate and CAG 
combination, respectively.
The treatment of 3,4-DGE-damaged endothelial cells 
with citrate or CAG combination significantly reduced total 
cell death to 35% (Figure 1b). The effect was most promi-
nent on 3,4-DGE-induced necrosis, which was reduced to 
25% with citrate treatment and to 26% with the CAG com-
bination. 3,4-DGE-induced endothelial apoptosis was 
reduced to 9% with both citrate treatment alone or the CAG 
combination (Figure 1b and Figure 2b). The addition of cit-
rate or CAG combination to control endothelial cells did 
not affect cell viability (data not shown).
Figure 3.  Citrate and the 0.8 mM citrate and 1 mM gluconate (CAG) combination decrease intercellular adhesion molecule-1 
(ICAM-1) expression. ICAM-1 expression was analysed by flow cytometry on glucose or 3,4-DGE-treated endothelial cells and in 
the damaged cells in the presence of citrate or the CAG combination. Endothelial ICAM-1 expression after treatment with glucose 
and citrate (a), glucose and CAG combination (b), 3,4-DGE and citrate (c) and 3,4-DGE and CAG combination (d). Immunoglobulin 
G (IgG) negative control was used as the control. ICAM-1 expression was significantly upregulated by glucose or 3,4-DGE treatment 
(shift to the right). Addition of the CAG combination significantly decreased glucose or 3,4-DGE-induced ICAM-1 expression (shift 
to the left), while the addition of citrate only decreased glucose-induced ICAM-1 expression. The results are from one representative 
experiment out of a total of four experiments.
Table 1.  ICAM-1 expression on endothelial cells
Additive to the cells Meana ± SEM p value
None 8.8 0.08 –
Glucose 9.5 0.01 < 0.01b
Glucose and citrate 9.0 0.04 < 0.01c
Glucose and citrate/gluconate 8.7 0.01 < 0.01c
3,4-DGE 9.8 0.04 < 0.05b
3,4-DGE and citrate 9.6 0.01 nsd
3,4-DGE and citrate/gluconate 8.5 0.04 <0.05e
3,4-DGE: 3,4-dideoxyglucosone-3-ene, ICAM-1: intercellular adhesion 
molecule-1.
aThe results are the mean (± SEM) of four separate experiments; 
bcompared to the negative control; ccompared to glucose-treated cells; 
dcompared to 3,4-DGE- and citrate-treated cells (ns = not significant); 
ecompared to 3,4-DGE- and citrate/gluconate-treated cells.Bryland et al.  47
Citrate decreases PKC-βII expression
PKC activation is involved in the development of vascular 
dysfunction and plays a key role in the pathophysiology of 
diabetic vascular complications. Endothelial treatment with 
glucose or 3,4-DGE increased PKC-βII expression com-
pared to unstimulated cells (Figure 2b and 2c). The addition 
of citrate or CAG combination during endothelial treatment 
with glucose or 3,4-DGE kept PKC-βII expression down to 
background level.
Citrate decreases endothelial ICAM-1 
expression
We investigated if citrate treatment of endothelial cells dur-
ing conditions of hyperglycaemia affects ICAM-1 and 
VCAM-1. Exposure of endothelial cells to glucose or 3,4-
DGE significantly upregulated ICAM-1 expression (Figure 3 
and Table 1), but did not affect VCAM-1 expression (data 
not shown). Glucose-induced ICAM-1 expression was sig-
nificantly reduced with the addition of citrate or CAG com-
bination. ICAM-1 expression was also reduced by the 
presence of CAG combination in 3,4-DGE-damaged cells. 
However, gluconate alone did not reduce glucose or 
3,4-DGE-increased endothelial ICAM-1 expression, and 
citrate alone did not reduce 3,4-DGE-increased endothelial 
ICAM-1 expression. Treatment of control endothelial cells 
with citrate, gluconate or CAG combination did not increase 
ICAM-1 expression (data not shown).
Citrate decreases neutrophil migration 
across infected cells
To investigate how glucose and 3,4-DGE affect endothelial 
cell function, we cultured HUVECs in the Transwell® 
model and investigated if infection-induced neutrophil 
diapedesis could be affected by glucose (Figure 4a) or 3,4-
DGE (Figure 4b) in the presence or absence of citrate or 
CAG combination. Infection increased neutrophil diapede-
sis by 48%, but was not further affected by glucose or 3,4-
DGE treatment. However, neutrophil migration was 
significantly reduced by citrate or CAG treatment of 
infected and glucose or 3,4-DGE-treated endothelial cells 
(p < 0.01 and p < 0.001). Treatment of infected endothe-
lium with citrate or CAG combination reduced neutrophil 
diapedesis to the same extent, while neither citrate nor 
CAG combination treatment of non-infected control cells 
had any effect (data not shown).
Citrate decreases inflammation
Endothelial cells were treated with glucose or 3,4-DGE 
with or without citrate or CAG combination to further 
investigate the effect of glucose and 3,4-DGE on endothe-
lial dysfunction during inflammation. Secretion of the pro-
inflammatory cytokine, IL-6, and the chemotactic cytokine, 
CXCL8, was used as a model of inflammation. Basal IL-6 
secretion (negative control) was 33  pg/ml (Figure 5a and 
5b). An infection significantly increased IL-6 secretion to 
146  pg/ml and IL-6 secretion increased even further to 
235 pg/ml with glucose (Figure 5a) and to 208 pg/ml with 
3,4-DGE (Figure 5b). Using citrate alone on infected 
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Figure 4.  Citrate and the 0.8 mM citrate and 1 mM gluconate 
(CAG) combination decrease neutrophil diapedesis across 
infected cells. Endothelial cells were grown in glucose (grey) 
(panel a) or 3,4-DGE (grey) (panel b) alone or in the presence 
of citrate (dashed) and CAG combination (dotted) for 2 days 
before the addition of human neutrophils to the upper 
compartment of activated monolayers. Migrated neutrophils 
were calculated in the lower compartment after 3 h. (a) The 
addition of citrate and CAG combination decreased neutrophil 
migration across infected endothelial cells, but glucose treatment 
did not have any influence. (b) The 3,4-DGE treatment of 
endothelial cells had a small impact on neutrophil migration that 
was further reduced by citrate or CAG combination treatment. 
Cells grown in medium alone were used as a negative control 
(white) and untreated infected cells were used as positive 
control (black). The results are the mean (± SEM) of three 
different experiments (***p < 0.001, **p < 0.01, *p < 0.05, 
ns = not significant).48  Diabetes & Vascular Disease Research 9(1)
endothelial cells in the presence of glucose or 3,4-DGE 
reduced IL-6 secretion to 173 and 135 pg/ml and the CAG 
combination reduced cytokine secretion even further to 138 
and 118 pg/ml, respectively (Figure 5a and 5b). The CAG 
combination significantly decreased the level of IL-6 secre-
tion from non-infected endothelial cells while citrate treat-
ment alone had a lesser effect, 138  pg/ml and 173  pg/ml, 
respectively (p = 0.048, data not shown).
Endothelial cells secrete the neutrophil chemokine 
CXCL8 upon infection. The basal level of CXCL8 in con-
trol samples was 295 pg/ml, which increased to 1354 pg/ml 
upon infection. Glucose or 3,4-DGE treatment of infected 
endothelial cells increased CXCL8 secretion slightly more, 
but the increase was not significant. Citrate treatment of 
infected cells exposed to glucose or 3,4-DGE did not 
decrease CXCL8 secretion significantly. However, the 
CAG combination significantly decreased CXCL8 secre-
tion from infected cells exposed to glucose or 3,4-DGE to 
788 and 576  pg/ml, respectively (p < 0.05 and p < 0.01 
respectively).
Discussion
Endothelial dysfunction is an early manifestation of vascu-
lar atherosclerosis and cardiovascular disease. Confirming 
previous studies, we found that hyperglycaemia and 3,4-
DGE significantly increased both necrosis and apoptosis, 
with 3,4-DGE causing the highest cell death. To evaluate 
the capacity of citrate and gluconate on endothelial sur-
vival, hyperglycaemia-damaged endothelial cells were 
treated with these compounds and analysed for apoptosis 
and necrosis. Remarkably, we found that endothelial treat-
ment with citrate or with the CAG combination decreased 
hyperglycaemia and 3,4-DGE induced cell death by up to 
50%. The mechanism behind citrate-induced reduction in 
cell death was shown to involve a reduced PKC-βII expres-
sion. PKC-βII is a member of the superfamily of serine/
threonine kinases that respond to Ca2+ and diacylglycerol 
(DAG) for downstream signalling.30 To be activated, PKC 
must be properly phosphorylated, but while phosphoryla-
tions at the activation site are dispensable for activity, 
Figure 5.  Citrate and 0.8 mM citrate and 1 mM gluconate (CAG) combination decrease inflammation. Secretion of interleukin-6 
(IL-6) (a and b) and chemokine (C-X-C motif) ligand 8 (CXCL8) (c and d) from endothelial cells treated with glucose (grey) 
(panel c) or 3,4-DGE (grey) (panel d) alone or in the presence of citrate (dashed) or CAG combination (dotted). The presence 
of citrate and CAG combination decreased glucose- and 3,4-DGE-induced IL-6 secretion (a and b). CXCL8 secretion was not 
affected by glucose or 3,4-DGE treatment of endothelial cells, but the presence of citrate decreased endothelial CXCL8 secretion 
(c and d). Cells grown in medium alone were used as a negative control (white) and untreated infected cells were used as positive 
control (black). The results are the mean (±SEM) of three different experiments (**p < 0.01, *p < 0.05, ns = not significant).Bryland et al.  49
phosphorylation of the turn motif is absolutely required to 
maintain catalytic competence of the enzyme.31 Supporting 
our observations, blocking of the PKC pathway was previ-
ously shown to decrease hyperglycaemia-caused apopto-
sis.32 Citrate is also a well-known Ca2+ chelator and could 
thus decrease PKC activation by blocking the Ca2+-
mediated translocation of PKC from the cytosol to the 
membrane. Several clinical studies on vascular function in 
diabetic patients have shown that inhibition of the PKC-β 
pathway has beneficial effects on vascular blood flow.33,34 
However, the blocking of PKC-β did not affect the increased 
oxidative state in diabetic patients,34,35 suggesting that other 
isoforms of PKC, including alpha and delta, may partici-
pate in vascular dysfunction.36
Hyperglycaemia-induced expression of adhesion mole-
cules and the modulation of junctional permeability is one 
of the initial events of endothelial dysfunction and was 
recently shown to be mediated by the PKC pathways.19,37 In 
this study, both hyperglycaemia and 3,4-DGE were found 
to increase endothelial ICAM-1 expression, but the expres-
sion of VCAM-1 was not affected. Citrate treatment 
decreased both hyperglycaemia-induced ICAM-1 expres-
sion and hyperglycaemia-induced neutrophil diapedesis. 
However, citrate treatment did not decrease 3,4-DGE-
induced ICAM-1 expression, although 3,4-DGE-induced 
neutrophil diapedesis was decreased by citrate treatment. 
This discrepancy between ICAM-1 expression and neutro-
phil diapedesis could indicate that citrate affects additional 
mechanisms involved in neutrophil diapedesis. On the 
other hand, the CAG combination exhibited a highly sig-
nificant decrease of both hyperglycaemia- and 3,4-DGE-
induced ICAM-1 expression. Furthermore, the combination 
significantly decreased both hyperglycaemia and 3,4-DGE-
induced neutrophil diapedesis. These findings supports a 
previous report indicating that citrate improves the effect of 
other antioxidants.38
A recent study in septic patients with hyperglycaemia 
showed increased neutrophil chemotaxis due to an increase 
of adhesion molecules.39 Furthermore, chemokine-driven 
leukocyte invasion of hyperglycaemic dysfunctional 
endothelium gives rise to inflammation and plaque forma-
tion.40 We observed only a minor increase of IL-6 and 
CXCL8 from hyperglycaemia- or 3,4-DGE-damaged cells 
in the infection model. Treatment with citrate significantly 
decreased IL-6 secretion from infected cells, but CXCL8 
secretion was not significantly affected. However, the 
CAG combination decreased both cytokines, although the 
combination had the most impact on 3,4-DGE-induced 
CXCL8 secretion. Apart from the chelating capacities of 
citrates and gluconates, the positive effects of these com-
pounds can originate from their quality as free radical scav-
engers,41,42 thereby blocking hyperglycaemia-induced ROS 
production.7,32,43 Additionally, citrate is known to maintain 
the glutathione (GSH)/oxidised glutathione (GSSG) ratio, 
the central component of the myocardial antioxidant sys-
tem (reviewed by Mallet et al.).38
To the best of our knowledge, this is the first study ana-
lysing the impact of citrate treatment on hyperglycaemia-
damaged endothelial cells. Here we demonstrate that citrate 
treatment alone, or in combination with gluconate, 
decreases PKC-IIβ expression and mitigates both necrosis 
and apoptosis in hyperglycaemia- or 3,4-DGE-damaged 
cells. Citrate treatment was also shown to decrease endothe-
lial inflammation by reducing ICAM-1 expression and 
cytokine production. Furthermore, the presence of citrate 
during hyperglycaemic conditions was shown to improve 
endothelial function by decreasing neutrophil diapedesis. 
Although very promising, these in vitro results should be 
correlated with in vivo studies using animal models. In 
summary, these results suggest that citrate alone or in com-
bination with gluconate can aid potential therapeutic 
approaches to endothelial dysfunction induced by 
hyperglycaemia.
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